TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33339304

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (600 IU daily)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Enhanced vitamin D2 in a mushroom matrix (D2M)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Standard mushroom (SM)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 436
Study: 34715650

Group type: EXPERIMENTAL
Intervention: (−)-OSU6162 30-60 mg/day for 12 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: (−)-OSU6162 with concomitant antidepressants
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: (−)-OSU6162 with beta- or calcium-channel blockers
Number of subjects: 96
Study: 33189635

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 36413549

Group type: EXPERIMENTAL
Intervention: Nudge message reminding people of familial support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no nudge message)
Number of subjects: 0
Study: 34221620

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) - 20 mg/kg bolus over 20 min followed by 1 mg/kg/h infusion until surgical wound closure
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA)
Number of subjects: 91
Study: 32702748

Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 58390

Group type: EXPERIMENTAL
Intervention: Simvastatin dose and other risk factors
Number of subjects: 58390

Group type: EXPERIMENTAL
Intervention: Myopathy risk score
Number of subjects: 58390

Group type: EXPERIMENTAL
Intervention: SLCO1B1 genotype
Number of subjects: 58390
Study: 34289183

Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 75
Study: 34494112

Group type: EXPERIMENTAL
Intervention: Plant-based diet plus eggs (2 eggs daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Exclusively plant-based diet (without eggs)
Number of subjects: 35
Study: 36228177

Group type: EXPERIMENTAL
Intervention: Standing Order Entry (SOE) to prescribe PP-CSF (n = 542)
Number of subjects: 846

Group type: COMPARATOR
Intervention: Alert to not prescribe PP-CSF (n = 304)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Both groups (SOE and Alert)
Number of subjects: 846
Study: 33322949

Group type: EXPERIMENTAL
Intervention: Baska Mask
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 60
Study: 35584804

Group type: EXPERIMENTAL
Intervention: Low-frequency whole-body vibration (WBV) at 4, 8, 12, 16, 24, and 30 Hz
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-frequency whole-body vibration (WBV)
Number of subjects: 20
Study: 34235906

Group type: EXPERIMENTAL
Intervention: Micro-SCTG harvesting (test group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Macro-SCTG harvesting (control group)
Number of subjects: 16
Study: 35810822

Group type: EXPERIMENTAL
Intervention: Varied context group (VARI)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Constant context group (CONS)
Number of subjects: 49
Study: 33148972

Group type: EXPERIMENTAL
Intervention: β-alanine (6.4 g·d‐1 for 8 wk)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: β-alanine
Number of subjects: 15
Study: 32285513

Group type: EXPERIMENTAL
Intervention: Psychosocial dementia care programme (DEMBASE®)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Facilitators identified
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Barriers identified
Number of subjects: 157
Study: 33239521

Group type: EXPERIMENTAL
Intervention: Orthopaedic-specific question prompt list (QPL) with 45 total questions
Number of subjects: 156

Group type: COMPARATOR
Intervention: AskShareKnow model questions (control)
Number of subjects: 156
Study: 35070226

Group type: EXPERIMENTAL
Intervention: Modified Wenjing decoction combined with online publicity and education
Number of subjects: 111

Group type: COMPARATOR
Intervention: Online publicity and education and conventional treatment (Control)
Number of subjects: 111
Study: 33031175

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target 130-140 mmHg)
Number of subjects: 1311

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure management (<180 mmHg)
Number of subjects: 1311
Study: 36037752

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (HIRT) twice weekly for 12 weeks (group A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (HIRT) once weekly for 12 weeks (group B)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combined HIRT groups (A and B)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Non-intervention control group (n=69)
Number of subjects: 71
Study: 32600858

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed formula (pHF) with reduced lactose content and Lactobacillus reuteri DSM 17938 (L. reuteri)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 241
Study: 35895362

Group type: EXPERIMENTAL
Intervention: Single dose azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7-day course of amoxicillin
Number of subjects: 0
Study: 33495853

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Secondary outcomes (not specified as I or C)
Number of subjects: 222
Study: 34648187

Group type: EXPERIMENTAL
Intervention: Nivolumab 0.3 mg/kg every 3 weeks
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 4 weeks
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg every 8 weeks
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 6 weeks
Number of subjects: 1000
Study: 34767573

Group type: EXPERIMENTAL
Intervention: Pregnancy self-testing obtained from a pharmacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Employment status, partner's education level, travel time to MCH clinic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reasons for non-use of pregnancy self-tests
Number of subjects: 0
Study: 35237844

Group type: EXPERIMENTAL
Intervention: EHR alert for cardiovascular disease and stroke risk management
Number of subjects: 7190

Group type: COMPARATOR
Intervention: Usual EHR usage (control group)
Number of subjects: 7190
Study: 32833479

Group type: EXPERIMENTAL
Intervention: TAU + App-Based Mindfulness Training (Unwinding Anxiety app)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 80
Study: 36939661

Group type: EXPERIMENTAL
Intervention: Atrial shunt procedure
Number of subjects: 626

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 626
Study: 33768603

Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Triprolidine 5 mg
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 34179941

Group type: EXPERIMENTAL
Intervention: 2D high resolution stress CMR (spatial resolution 1.2 mm2)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3D whole heart stress CMR (in-plane spatial resolution 2.3 mm2)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 2D high resolution vs. 3D whole heart
Number of subjects: 38
Study: 33752431

Group type: EXPERIMENTAL
Intervention: IV catheter with PosiFlow regulator and infusion clip
Number of subjects: 960

Group type: COMPARATOR
Intervention: IV catheter with infusion clip
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: IV catheter without infusion clip
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: IV catheter with PosiFlow regulator
Number of subjects: 960
Study: 35042081

Group type: EXPERIMENTAL
Intervention: V591 (1×105 TCID50)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: V591 (1×106 TCID50)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: V591 (1×107 TCID50)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 32493344

Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 33175980

Group type: EXPERIMENTAL
Intervention: 30‐min Yoga Nidra plus 60‐min lying quietly
Number of subjects: 22

Group type: COMPARATOR
Intervention: 90‐min lying quietly
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Self-reported mood and anxiety
Number of subjects: 22
Study: 615261555

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36343870

Group type: EXPERIMENTAL
Intervention: AM exercise (8:00–10:00)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PM exercise (17:00–19:00)
Number of subjects: 45
Study: 33876883

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (1 × 10^7 cells/kg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 32697510

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (3×5 min, 3×7 min, 3×10 min, or 3×5 min + 2×10 min in nonresponders)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sham-remote ischemic preconditioning (control)
Number of subjects: 180
Study: 35511285

Group type: EXPERIMENTAL
Intervention: Ash‐Kardeh (250 g daily for 6 weeks)
Number of subjects: 46
Study: 34229057

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 219
Study: 35151397

Group type: EXPERIMENTAL
Intervention: Casirivimab 4 g and imdevimab 4 g administered together in a single intravenous infusion plus usual care
Number of subjects: 9785

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 9785

Group type: EXPERIMENTAL
Intervention: Casirivimab and imdevimab plus usual care
Number of subjects: 9785
Study: 33761625

Group type: EXPERIMENTAL
Intervention: Extended-release niacin for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo for 3 months
Number of subjects: 0
Study: 32448089

Group type: EXPERIMENTAL
Intervention: direct endovascular treatment
Number of subjects: 194

Group type: COMPARATOR
Intervention: bridging therapy (intravenous recombinant tissue-type plasminogen activator)
Number of subjects: 194
Study: 35368914

Group type: EXPERIMENTAL
Intervention: Human adipose derived mesenchymal stem cells treatment for each 10 cm² of wound
Number of subjects: 346

Group type: COMPARATOR
Intervention: Conventional dressing with normal saline for each 10 cm² of wound
Number of subjects: 346
Study: 32372176

Group type: EXPERIMENTAL
Intervention: Subcutaneous testosterone pellet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical testosterone gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo pellet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study: 33629920

Group type: EXPERIMENTAL
Intervention: Foster care intervention during infancy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Medium-Morbidity profile
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Low-Morbidity profile
Number of subjects: 165
Study: 32808403

Group type: EXPERIMENTAL
Intervention: Active tDCS and rehabilitation with complex walking tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS and rehabilitation with complex walking tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS and rehabilitation with typical walking
Number of subjects: 0
Study: 34709659

Group type: EXPERIMENTAL
Intervention: MDT intervention (GNS-facilitated multidisciplinary team)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: MDT intervention
Number of subjects: 400
Study: 36510155

Group type: EXPERIMENTAL
Intervention: Nutritional education programme with high content of prebiotics and probiotics (dairy and fermented foods, green leafy vegetables, high-fibre fruit, whole grains, etc.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional dietary counselling
Number of subjects: 50
Study: 32957748

Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy
Number of subjects: 293
Study: 35963491

Group type: EXPERIMENTAL
Intervention: Global Symptoms cluster (high psychosocial scores, moderate PPT)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Adaptive cluster (low psychosocial scores, high PPT)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Pain Sensitive cluster (moderate psychosocial scores, low PPT)
Number of subjects: 228
Study: 32998837

Group type: EXPERIMENTAL
Intervention: 2-week online oral anticoagulant counseling training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pre-intervention quality of counseling
Number of subjects: 33
Study: 35535023

Group type: EXPERIMENTAL
Intervention: Age-based stereotype threat (ABST)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 32568367

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU daily for 12 months)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo (diluent, daily for 12 months)
Number of subjects: 289
Study: 34001750

Group type: EXPERIMENTAL
Intervention: Multidose (MTD) containers
Number of subjects: 173

Group type: COMPARATOR
Intervention: Single-dose (SGD) containers
Number of subjects: 173

Group type: COMPARATOR
Intervention: SGD instillation
Number of subjects: 173
Study: 33757615

Group type: EXPERIMENTAL
Intervention: Tailored Activity Program (TAP)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: TAP
Number of subjects: 250
Study: 35109430

Group type: EXPERIMENTAL
Intervention: Mentalizing Imagery Therapy (MIT)
Number of subjects: 12
Study: 32289673

Group type: EXPERIMENTAL
Intervention: Active rTMS (20 sessions, 4-week course of 20 Hz rTMS targeting dorsolateral prefrontal cortex at 90% RMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study: 36054285

Group type: EXPERIMENTAL
Intervention: Customized allogeneic bone blocks (CABB group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Autogenous bone blocks (ABB group)
Number of subjects: 24
Study: 33831950

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER) - 2 days per week, 500 kcal (2100 kJ)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Continuous energy restriction (CER) - daily, 1500 kcal (6000 kJ)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both IER and CER
Number of subjects: 121
Study: 35545816

Group type: EXPERIMENTAL
Intervention: ZFR00V IOLs
Number of subjects: 150

Group type: COMPARATOR
Intervention: TFNT00 IOLs
Number of subjects: 150
Study: 32447618

Group type: EXPERIMENTAL
Intervention: Lung-ultrasound-guided dry-weight reduction
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 71
Study: 35210082

Group type: EXPERIMENTAL
Intervention: Pacemaker
Number of subjects: 115

Group type: COMPARATOR
Intervention: ICM
Number of subjects: 115
Study: 32640097

Group type: EXPERIMENTAL
Intervention: Vibration Anesthetic Device (VAD) during mesotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Vibration Anesthetic Device (Control) during mesotherapy
Number of subjects: 30
Study: 35175346

Group type: EXPERIMENTAL
Intervention: Reserved message (text stating 'a flu shot has been reserved for you')
Number of subjects: 11188

Group type: EXPERIMENTAL
Intervention: Available message (text stating 'flu shots will be available')
Number of subjects: 11188

Group type: EXPERIMENTAL
Intervention: Reserved message
Number of subjects: 11188

Group type: EXPERIMENTAL
Intervention: Patients who replied Y
Number of subjects: 11188

Group type: COMPARATOR
Intervention: Usual care (no message)
Number of subjects: 11188
Study: 34135047

Group type: EXPERIMENTAL
Intervention: Telephone consultations for EMA
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Face-to-face consultations for EMA
Number of subjects: 1222
Study: 32798022

Group type: EXPERIMENTAL
Intervention: Weekly panitumumab + chemoradiotherapy during induction
Number of subjects: 126

Group type: COMPARATOR
Intervention: Chemoradiotherapy alone during induction
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Anatomic resection
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Minimally invasive resections
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Overall surgical adverse events
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 30-day mortality
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 90-day mortality
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Extended resection
Number of subjects: 126
Study: 35178117

Group type: EXPERIMENTAL
Intervention: Refined nursing management methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional nursing management methods
Number of subjects: 0
Study: 33651091

Group type: EXPERIMENTAL
Intervention: Blinatumomab (15 μg/m2/d for 4 weeks, continuous intravenous infusion)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Consolidation chemotherapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 108
Study: 36455168

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study: 34248023

Group type: EXPERIMENTAL
Intervention: Near-infrared‐assisted total thyroidectomy with indocyanine green (ICG) angiography
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard total thyroidectomy
Number of subjects: 58
Study: 32032355

Group type: EXPERIMENTAL
Intervention: Genetic test for lifetime risk of prostate cancer (based on genotyping of 33 risk‐associated single nucleotide polymorphisms) in intervention practices.
Number of subjects: 7800

Group type: COMPARATOR
Intervention: Standard PSA test without genetic risk assessment in control practices.
Number of subjects: 7800
Study: 36383742

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Midazolam placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Oral benzodiazepines (considered as a binary predictor)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Oral benzodiazepines (considered as a continuous predictor)
Number of subjects: 99
Study: 32578850

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily for 12 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 66
Study: 35407540

Group type: EXPERIMENTAL
Intervention: Follow-up by a cardiologist and a geriatrician (intervention)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care by a cardiologist (control)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall hospitalization
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 150
Study: 32845087

Group type: EXPERIMENTAL
Intervention: Cognitive dissonance-based weight stigma intervention
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study: 34800700

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy (durvalumab plus tremelimumab)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Immunotherapy (durvalumab plus tremelimumab)
Number of subjects: 301
Study: 33314886

Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein supplement (2:2 ratio)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein supplement (3:1 ratio)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 32790701

Group type: EXPERIMENTAL
Intervention: cfPWV
Number of subjects: 6734

Group type: EXPERIMENTAL
Intervention: baPWV
Number of subjects: 6734

Group type: EXPERIMENTAL
Intervention: bfPWV
Number of subjects: 6734
Study: 35940551

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention including five group education sessions on DMII and HTN management and two one-on-one goal setting sessions.
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 195
Study: 33351701

Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 86
Study: 35685538

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron (Group O)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 2 mL saline (Group S)
Number of subjects: 55
Study: 34992867

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin chemotherapy (40 mg/m2/cycle, 5 cycles)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Three weekly cisplatin chemotherapy (100 mg/m2/cycle, 2 cycles)
Number of subjects: 212
Study: 34581459

Group type: EXPERIMENTAL
Intervention: Individual neuropsychological intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group neuropsychological intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both interventions (individual and group)
Number of subjects: 120
Study: 32534369

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and azithromycin (first-choice treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxychloroquine or chloroquine
Number of subjects: 0
Study: 35799258

Group type: EXPERIMENTAL
Intervention: Sedentary Behaviour Intervention (SB-I)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Physical Activity + Sedentary Behaviour Intervention (PA + SB-I)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Usual Practice (Control)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention (PA-I)
Number of subjects: 267
Study: 32517497

Group type: EXPERIMENTAL
Intervention: Icare rebound tonometer
Number of subjects: 1266

Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 1266
Study: 36315419

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 239
Study: 33845980

Group type: EXPERIMENTAL
Intervention: Approximate arithmetic training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visuo-spatial working memory training
Number of subjects: 0